Clinical trials: completed, sponsored by Bayer
Peripheral Artery Disease
A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients
This is a study to learn more about French patients who have peripheral artery disease (PAD) and who have had a revascularization procedure.
- Trial name
- PADELTO (NCT04824729)
- Testing
- Lower limb revascularization
- Where
- France
- Volunteers
- 227,613 people
- Sponsor
- Bayer
Renal Insufficiency, Chronic
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
In this survey study, researchers want to find out more about how physicians are treating patients diagnosed with reduced kidney function (chronic kidney disease, CKD) and high blood sugar level (type 2 diabetes); what physicians…
- Trial name
- AWARE-CKD (NCT04498156)
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bayer
Gastrointestinal Cancer
Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer
In this study, researchers wanted to learn more about the effect of Aspirin taken as low dose (75 - 300 mg) in preventing stomach, colorectal and esophagus cancer.
- Trial name
- ENgAGE-HK (NCT04081831)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- Hong Kong
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Heart Failure (HF)
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
- Trial name
- AVANTI (NCT03901729)
- Testing
- BAY 1753011, Furosemide
- Where
- 66 sites in Austria, Bulgaria and 7 more
- Volunteers
- 482 people
- Sponsor
- Bayer
Diabetic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when…
- Trial name
- FIGARO-DKD (NCT02545049)
- Testing
- Finerenone (BAY94-8862)
- Where
- 975 sites in United States, Argentina and 46 more
- Volunteers
- 7,352 people
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors
Regorafenib Post-marketing Surveillance in Japan
The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice
- Trial name
- NCT01933958
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Cancer
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
The purpose of this study is to enable patients, who are currently receiving rogaratinib in a Bayer-sponsored clinical trial (incl. NCT01976741), to continue treatment after their respective study has been closed.
- Trial name
- NCT04125693
- Testing
- Rogaratinib (BAY1163877), Combination drug
- Where
- Switzerland
- Volunteers
- 1 people
- Sponsor
- Bayer
Metastatic Castration Resistant Prostate Cancer (mCRPC)
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other…
- Trial name
- EPIX (NCT04516161)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- United States
- Volunteers
- 1,180 people
- Sponsor
- Bayer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults
Researchers are looking for a new way to treat women who have symptoms that are caused by the sex hormonal changes that happen when a woman's body is going through the menopause.
- Trial name
- NCT04981431
- Testing
- Elinzanetant (BAY3427080)
- Where
- Japan
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Bayer
Allergic Rhinitis
Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis
In this study researchers want to learn how quickly patients suffering from allergic rhinitis (also known as hay fever) can expect symptom relief after using Azelastine Hydrochloride 0.15% Nasal Spray.
- Trial name
- NCT04264637
- Testing
- Azelastine hydrochloride (BAYR9258)
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Bayer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants
Researchers are looking for a better way to treat people who have symptoms caused by hormonal changes, like those that happen in women during menopause. These symptoms can include vasomotor symptoms.
- Trial name
- NCT04903821
- Testing
- BAY3427080
- Where
- 2 sites in Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Non-Valvular Atrial Fibrillation
A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
Atrial fibrillation is a heart condition that causes an abnormal and fast heart rate. For people with non-valvular atrial fibrillation (NVAF), this is caused by problems such as high blood pressure and diabetes.
- Trial name
- BELANCE (NCT04722679)
- Testing
- Non-VKA Oral Anticoagulants (NOAC)
- Where
- Belgium
- Volunteers
- 103 people
- Sponsor
- Bayer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults
Researchers are looking for a better way to treat people who have vasomotor symptoms (VMS). VMS such as hot flashes are caused by hormonal changes occurring during menopausal transition when women may have also changes in their…
- Trial name
- NCT05061563
- Testing
- Elinzanetant (BAY3427080), Esomeprazole
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Renal Dialysis
End-stage Renal Disease (ESRD) Pilot Study
The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD).
- Trial name
- NCT03787368
- Testing
- BAY1213790, 0.9% sodium chloride solution
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 55 people
- Sponsor
- Bayer
Diabetic Kidney Disease
A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in type II diabetic patients with a clinical…
- Trial name
- CADA DIA (NCT03412006)
- Testing
- Fulacimstat (BAY1142524)
- Where
- 27 sites in Bulgaria, Denmark and 5 more
- Volunteers
- 152 people
- Sponsor
- Bayer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.
Researchers are looking for a better way to treat people who have symptoms caused by hormonal changes, such as hot flashes. Before a treatment can be approved for patients to take, researchers do clinical studies to better…
- Trial name
- NCT05028608
- Testing
- Elinzanetant (BAY3427080), Midazolam, Carbamazepine
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Heart Failure
BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally
- Trial name
- ARTS (NCT01345656)
- Testing
- BAY94-8862, Spironolactone
- Where
- 50 sites in Austria, Belgium and 8 more
- Volunteers
- 457 people
- Sponsor
- Bayer
Clinical Pharmacology
Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862
Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.
- Trial name
- NCT01473108
- Testing
- Finerenone (BAY 94-8862) PEG solution, Finerenone (BAY 94-8862) immediate release tablet, Eplerenone (Inspra®)
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Bayer
Heart Failure
Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets
This study should estimate the dose proportionality of BAY94-8862 IR tablets.
- Trial name
- NCT01687920
- Testing
- BAY94-8862 (1.25mg), BAY94-8862 (2.5mg), BAY94-8862 (5mg)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Worsening Chronic Heart Failure, Chronic Kidney Disease
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should.
- Trial name
- NCT04908436
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.